Annuncio • Aug 23
L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO). L.I.A. Pure Capital Ltd. proposed to acquire remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) for $3.5 million on March 4, 2025. The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share. The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective. The Court has given the Company until March 12, 2025, to submit a response to the Amended Request. The parties will finalize the Arrangement only if the parties satisfy or waive certain conditions including Israeli court approval. The board of directors of Xylo Technologies Ltd has decided not to object and has approved the proposal, considering it to be fair. As of May 27, 2025, Xylo Technologies Ltd shareholders approved the transaction in the general meeting. The transaction remains subject to approval by the Tel Aviv District Court.
As of June 05, 2025, Viewbix Inc. has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. As of June 22, 2025, the district court of Tel Aviv approved the arrangement between Xylo and its shareholders.
L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) on August 22, 2025. New Risk • May 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Market cap is less than US$10m (US$6.66m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Reported Earnings • May 02
Full year 2024 earnings released: US$8.10 loss per share (vs US$25.34 loss in FY 2023) Full year 2024 results: US$8.10 loss per share (improved from US$25.34 loss in FY 2023). Revenue: US$29.9m (down 67% from FY 2023). Net loss: US$6.03m (loss narrowed 62% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. New Risk • Apr 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.66m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Nancy Agmon-Levin was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Sep 26
First half 2024 earnings released: US$11.33 loss per share (vs US$13.39 loss in 1H 2023) First half 2024 results: US$11.33 loss per share (improved from US$13.39 loss in 1H 2023). Revenue: US$19.3m (down 64% from 1H 2023). Net loss: US$8.17m (flat on 1H 2023). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 23
Full year 2023 earnings released: US$9.50 loss per share (vs US$6.04 loss in FY 2022) Full year 2023 results: US$9.50 loss per share (further deteriorated from US$6.04 loss in FY 2022). Revenue: US$91.7m (flat on FY 2022). Net loss: US$16.0m (loss widened 63% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 9 percentage points per year, which is a significant difference in performance. Annuncio • Apr 19
Medigus Ltd.(NasdaqCM:MDGS) dropped from NASDAQ Composite Index MediGus Ltd. has been removed from Nasdaq Composite Index. New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$4.74m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Annuncio • Dec 26
Medigus Ltd. Announces Launch of Unique Pilot of A Wireless Charging Solution Medigus Ltd. announced the launch of a unique pilot of a wireless charging solution to meet the growing demand for electric vehicle (EV) charging in automated parking systems. This project was led by Charging Robotics Ltd., an innovator in wireless charging solutions and a subsidiary of Fuel Doctor Holdings Inc., a Delaware corporation listed on the OTC Market and owned by Medigus (67.15%). Charging Robotics specializes in developing cutting-edge wireless charging solutions designed to seamlessly integrate into the evolving landscape of electric vehicle (EV) infrastructure. Charging Robotics is at the forefront of innovation, focusing on the creation of wireless charging systems that can be deployed in various settings, including automated parking systems. In August 2023, the company announced that it started a pilot project with an automatic car park provider in Israel to evaluate Charging Robotics' wireless charging system for electric vehicles. For that purpose, in November 2023, the company secured funding from the Israel Innovation Authority to fund the pilot project. Between 2023 and 2032, this market is estimated to register a CAGR of 11.4%. Alongside the expected growth in the EV market, the combination of EVs and automated parking creates potential for a more sustainable and efficient future for transportation. The wireless charging system is set to answer the unmet need of charging EVs in automatic car parks. Automatic car parks are gaining popularity as they offer an ultra-efficient solution to park cars, while also reducing expensive real estate costs. However, since these are automated facilities, currently there is no way for the driver to connect a charging cable to the vehicle. This is a major concern and a market inhibit for automated parking manufacturers and EV manufacturers, particularly in areas where electric vehicles are growing rapidly- this is the con Charging Robotics aiming to address. Besides enabling EV charging in automatic car parks, the wireless charging system has numerous advantages, including: Seamless Integration: the wireless charging system will be seamlessly integrated into the automatic car park infrastructure, requiring minimal modifications to the existing layout. This ensures a minimum installation process while maximizing parking capacity. Convenient Charging Experience: drivers will start the system using a dedicated smart phone application, which will also notify the driver about the charging process. Scalability and Adaptability: the system's modular design enables easy scalability, allowing the parking lot operator to increase the number of chargers in the facility based on the number of electric vehicles. The system will be able to charge all electric vehicles at efficiencies of >93% which is outstanding for wireless charging systems. New Risk • Oct 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$7.58m market cap). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (5.8% increase in shares outstanding). New Risk • Jul 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$8.01m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Annuncio • Jul 01
Medigus Ltd., Annual General Meeting, Aug 07, 2023 Medigus Ltd., Annual General Meeting, Aug 07, 2023, at 10:00 US Eastern Standard Time. Location: Law Offices, 16 Abba Hillel Silver Rd. Ramat - Gan Israel Agenda: To consider approval of the re-election of Mr. Eli Cohen to serve as a director of the Company; to consider approval of a grant of restricted share units to the Company’s Chief Executive Officer, Chief Financial Officer and the Company’s directors; and Approval and ratification of the re-appointment of Brightman Almagor Zohar & Co., a member firm of Deloitte Touche Tohmatsu Limited, company's independent auditors for the year ending December 31, 2023, and its service until the next annual general meeting of shareholders to be held in 2024. Annuncio • Jun 08
existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million. existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023.
existing shareholders and office holders in ScoutCam completed the acquisition of 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023. Reported Earnings • May 06
Full year 2022 earnings released: US$6.04 loss per share (vs US$4.42 profit in FY 2021) Full year 2022 results: US$6.04 loss per share (down from US$4.42 profit in FY 2021). Revenue: US$91.9m (up US$81.7m from FY 2021). Net loss: US$9.82m (down 244% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target decreased to US$67.50 Down from US$90.00, the current price target is provided by 1 analyst. New target price is 781% above last closing price of US$7.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$6.45 compared to earnings per share of US$4.42 last year. Major Estimate Revision • Sep 30
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$12.4m to US$75.5m. EPS estimate fell from -US$0.02 to -US$0.43 per share. Medical Equipment industry in the US expected to see average net income growth of 9.6% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$0.55 over the past week. Reported Earnings • Sep 24
First half 2022 earnings released: US$0.15 loss per share (vs US$0.44 profit in 1H 2021) First half 2022 results: US$0.15 loss per share (down from US$0.44 profit in 1H 2021). Revenue: US$35.0m (up US$32.6m from 1H 2021). Net loss: US$3.59m (down 137% from profit in 1H 2021). Revenue is expected to decline by 49% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.8%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Reported Earnings • May 01
Full year 2021 earnings released: EPS: US$0.20 (vs US$0.65 loss in FY 2020) Full year 2021 results: EPS: US$0.20 (up from US$0.65 loss in FY 2020). Revenue: US$10.1m (up US$9.59m from FY 2020). Net income: US$6.79m (up US$11.1m from FY 2020). Profit margin: 67% (up from net loss in FY 2020). Over the next year, revenue is expected to shrink by 38% compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improved over the past week After last week's 25% share price gain to US$1.10, the stock trades at a trailing P/E ratio of 3.3x. Average forward P/E is 34x in the Medical Equipment industry in the US. Total loss to shareholders of 62% over the past three years. Valuation Update With 7 Day Price Move • Nov 23
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$1.22, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 35x in the Medical Equipment industry in the US. Total loss to shareholders of 64% over the past three years. Board Change • Oct 31
High number of new directors Independent Chairman of the Board Eli Yoresh was the last director to join the board, commencing their role in 2020. Reported Earnings • Sep 26
First half 2021 earnings released: EPS US$0.44 (vs US$0.56 loss in 1H 2020) First half 2021 results: Net income: US$9.79m (up US$12.3m from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 10
New 90-day high: US$3.69 The company is up 84% from its price of US$2.01 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.